|
Securities Offered in This Offering
10,000,000 shares of our common stock
Offering Price
$1.00 per share
Common Stock to be Outstanding After This Offering
92,323,291 shares
Use of Proceeds
We intend to use the net proceeds from this offering primarily for the development of our lead product candidate, oliceridine, and for other general corporate purposes.
http://investors.trevena.com/node/9791/html
Trevena verliert "breakthrough designation" der FDA
seekingalpha.com/news/...s-breakthrough-designation-pain-drug
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
6 | 916 | Trevena - biopharmaceutical company +69,67 % | Balu4u | Dölauer | 19.07.23 17:35 | |
Nach dem Split | Dölauer | 11.11.22 12:44 | ||||
176 | Trevena FDA 2018 Olinvo | OlliCash | joker75 | 25.04.21 00:44 |